IPP Bureau
BASF Pharma Solutions excipient accepted into FDA Pilot Program
By IPP Bureau - December 06, 2022
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
JB Pharma reduces price of Azmarda by 50%
By IPP Bureau - December 06, 2022
Move to increase affordability and accessibility for heart failure patients across the country
Indira IVF to offer fertility perks for Indian corporate employees
By IPP Bureau - December 06, 2022
The service includes full fertility care benefits, including egg and embryo freezing options to employees
ANSSI Wellness inaugurates its new spine clinic in Pune
By IPP Bureau - December 06, 2022
Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune
ASG Eye Hospitals opens hospital in Vashi
By IPP Bureau - December 06, 2022
The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra
Auretics launched herbal cough syrup ‘Sedoril’
By IPP Bureau - December 06, 2022
It offers quick relief in various types of Coughs, Colds and Sore Throat,
Lonza’s API manufacturing facility expansion in Nansha starts commercial operation
By IPP Bureau - December 06, 2022
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Agilent opens customer experience center for genomics and diagnostics solutions
By IPP Bureau - December 06, 2022
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
Zydus receives final approval from USFDA for Estradiol Transdermal System
By IPP Bureau - December 05, 2022
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
By IPP Bureau - December 05, 2022
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
By IPP Bureau - December 05, 2022
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Merck to present data from Its hematology portfolio ASH meeting
By IPP Bureau - December 05, 2022
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Jemperli RUBY phase III trial met its primary endpoint
By IPP Bureau - December 05, 2022
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
EMA accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis
By IPP Bureau - December 05, 2022
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
World’s first intra-nasal vaccine for COVID developed by India has got approval from CDSCO
By IPP Bureau - December 02, 2022
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
